R A Blaheta
Overview
Explore the profile of R A Blaheta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mani J, Fleger J, Rutz J, Maxeiner S, Bernd A, Kippenberger S, et al.
Eur Rev Med Pharmacol Sci
. 2019 Dec;
23(23):10564-10574.
PMID: 31841214
Objective: Although the natural compound curcumin exerts antitumor properties in vitro, its clinical application is hampered due to rapid metabolism. Light exposure following curcumin application has been demonstrated to improve...
2.
Tsaur I, Makarevic J, Juengel E, Gasser M, Waaga-Gasser A, Kurosch M, et al.
Br J Cancer
. 2012 Jul;
107(5):847-55.
PMID: 22782340
Background: Inhibitors of the mammalian target of rapamycin (mTOR) might become a novel tool to treat advanced prostate cancer. However, chronic drug exposure may trigger resistance, limiting the utility of...
3.
Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro
Mani J, Vallo S, Barth K, Makarevic J, Juengel E, Bartsch G, et al.
Prostate Cancer Prostatic Dis
. 2012 Mar;
15(3):250-5.
PMID: 22450844
Background: The influence of the bisphosphonate zoledronic acid (ZA) on prostate cancer (PC) growth, adhesion and invasive behavior was investigated. Methods: PC-3, DU-145 and LNCaP cells were treated with ZA,...
4.
Juengel E, Bhasin M, Libermann T, Barth S, Michaelis M, Cinatl Jr J, et al.
World J Urol
. 2010 Jul;
29(6):779-86.
PMID: 20640575
Purpose: Renal cell carcinoma (RCC) is highly resistant to chemotherapy and unresponsive to radio- and immunotherapy. Recently, we have documented that the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) in combination...
5.
Tsaur I, Jones J, Melamed R, Blaheta R, Gossmann J, Bentas W
Transplant Proc
. 2009 Jun;
41(5):1615-8.
PMID: 19545691
Objective: To evaluate the incidence of voiding dysfunction in older male renal transplant recipients. Patients And Methods: Data for 103 patients aged 60 years or older (mean age, 65.7 years;...
6.
Wedel S, Mickuckyte A, Juengel E, Jones J, Hudak L, Jonas D, et al.
Urologe A
. 2008 Aug;
47(9):1175-81.
PMID: 18688594
Background: Conventional therapeutic approaches to treat advanced renal cell carcinoma (RCC) are of limited benefit. Receptor tyrosine kinase inhibitors (RTKI) may open up novel treatment options. In the present study,...
7.
Wedel S, Sparatore A, Soldato P, Al-Batran S, Atmaca A, Juengel E, et al.
J Cell Mol Med
. 2008 Feb;
12(6A):2457-66.
PMID: 18266964
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited...
8.
Blaheta R, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, et al.
Br J Cancer
. 2007 May;
96(11):1699-706.
PMID: 17505515
Drug resistance to chemotherapy is often associated with increased malignancy in neuroblastoma (NB). In pursuit of alternative treatments for chemoresistant tumour cells, we tested the response of multidrug-resistant SKNSH and...
9.
Engl T, Natsheh I, Muller I, Beecken W, Jonas D, Blaheta R
Int J Clin Pharmacol Ther
. 2004 Nov;
42(10):568-74.
PMID: 15516027
The branched-chain fatty acid valproate (valproic acid; VPA) displays antitumoral properties by blocking tumor growth, progression and invasion. Recent data have shown that VPA reduces the angiogenic activity of endothelial...
10.
Leckel K, Beecken W, Jonas D, Oppermann E, Coman M, Beck K, et al.
Clin Exp Immunol
. 2003 Nov;
134(2):238-45.
PMID: 14616783
Immunosuppression correlates with the development and recurrence of cancer. Mycophenolate mofetil (MMF) has been shown to reduce adhesion molecule expression and leucocyte recruitment into the donor organ. We have hypothesized...